Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients
Objectives:. Coronavirus disease 2019 is caused by severe acute respiratory syndrome-coronavirus-2 infection to which there is no community immunity. Patients admitted to ICUs have high mortality, with only supportive therapies available. Our aim was to profile plasma inflammatory analytes to help u...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wolters Kluwer
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2e2aee660c2348e2bff3b3144f7398a4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2e2aee660c2348e2bff3b3144f7398a4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2e2aee660c2348e2bff3b3144f7398a42021-11-25T07:51:35ZInflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients2639-802810.1097/CCE.0000000000000144https://doaj.org/article/2e2aee660c2348e2bff3b3144f7398a42020-06-01T00:00:00Zhttp://journals.lww.com/10.1097/CCE.0000000000000144https://doaj.org/toc/2639-8028Objectives:. Coronavirus disease 2019 is caused by severe acute respiratory syndrome-coronavirus-2 infection to which there is no community immunity. Patients admitted to ICUs have high mortality, with only supportive therapies available. Our aim was to profile plasma inflammatory analytes to help understand the host response to coronavirus disease 2019. Design:. Daily blood inflammation profiling with immunoassays. Setting:. Tertiary care ICU and academic laboratory. Subjects:. All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome-coronavirus-2, using standardized hospital screening methodologies, had daily blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative), or until ICU day 7 if the patient was positive (coronavirus disease 2019 positive). Interventions:. None. Measurements and Main Results:. Age- and sex-matched healthy controls and ICU patients that were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients were more likely than coronavirus disease 2019 negative patients to suffer bilateral pneumonia. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. We measured 57 inflammatory analytes and then analyzed with both conventional statistics and machine learning. Twenty inflammatory analytes were different between coronavirus disease 2019 positive patients and healthy controls (p < 0.01). Compared with coronavirus disease 2019 negative patients, coronavirus disease 2019 positive patients had 17 elevated inflammatory analytes on one or more of their ICU days 1–3 (p < 0.01), with feature classification identifying the top six analytes between cohorts as tumor necrosis factor, granzyme B, heat shock protein 70, interleukin-18, interferon-gamma-inducible protein 10, and elastase 2. While tumor necrosis factor, granzyme B, heat shock protein 70, and interleukin-18 were elevated for all seven ICU days, interferon-gamma-inducible protein 10 transiently elevated on ICU days 2 and 3 and elastase 2 increased over ICU days 2–7. Inflammation profiling predicted coronavirus disease 2019 status with 98% accuracy, whereas elevated heat shock protein 70 was strongly associated with mortality. Conclusions:. While many inflammatory analytes were elevated in coronavirus disease 2019 positive ICU patients, relative to healthy controls, the top six analytes distinguishing coronavirus disease 2019 positive ICU patients from coronavirus disease 2019 negative ICU patients were tumor necrosis factor, granzyme B, heat shock protein 70, interleukin-18, interferon-gamma-inducible protein 10, and elastase 2.Douglas D. Fraser, MD, PhDGediminas Cepinskas, DVM, PhDMarat Slessarev, MD, MScClaudio Martin, MD, MScMark Daley, PhDMichael R. Miller, PhDDavid B. O’Gorman, PhDSean E. Gill, PhDEric K. Patterson, PhDClaudia C. dos Santos, MD, MScon behalf of the Lawson COVID-19 Study TeamRobert ArntfieldIan BallGordon BarkwellTracey BentallKaren BosmaSaoirse CameronEileen CampbellDavid CarterCarolina Gillio-MeinaRobert HegeleNatalya OdoardiRam SinghKelly SummersSue TereschynWolters KluwerarticleMedical emergencies. Critical care. Intensive care. First aidRC86-88.9ENCritical Care Explorations, Vol 2, Iss 6, p e0144 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 |
| spellingShingle |
Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Marat Slessarev, MD, MSc Claudio Martin, MD, MSc Mark Daley, PhD Michael R. Miller, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Eric K. Patterson, PhD Claudia C. dos Santos, MD, MSc on behalf of the Lawson COVID-19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients |
| description |
Objectives:. Coronavirus disease 2019 is caused by severe acute respiratory syndrome-coronavirus-2 infection to which there is no community immunity. Patients admitted to ICUs have high mortality, with only supportive therapies available. Our aim was to profile plasma inflammatory analytes to help understand the host response to coronavirus disease 2019.
Design:. Daily blood inflammation profiling with immunoassays.
Setting:. Tertiary care ICU and academic laboratory.
Subjects:. All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome-coronavirus-2, using standardized hospital screening methodologies, had daily blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative), or until ICU day 7 if the patient was positive (coronavirus disease 2019 positive).
Interventions:. None.
Measurements and Main Results:. Age- and sex-matched healthy controls and ICU patients that were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients were more likely than coronavirus disease 2019 negative patients to suffer bilateral pneumonia. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. We measured 57 inflammatory analytes and then analyzed with both conventional statistics and machine learning. Twenty inflammatory analytes were different between coronavirus disease 2019 positive patients and healthy controls (p < 0.01). Compared with coronavirus disease 2019 negative patients, coronavirus disease 2019 positive patients had 17 elevated inflammatory analytes on one or more of their ICU days 1–3 (p < 0.01), with feature classification identifying the top six analytes between cohorts as tumor necrosis factor, granzyme B, heat shock protein 70, interleukin-18, interferon-gamma-inducible protein 10, and elastase 2. While tumor necrosis factor, granzyme B, heat shock protein 70, and interleukin-18 were elevated for all seven ICU days, interferon-gamma-inducible protein 10 transiently elevated on ICU days 2 and 3 and elastase 2 increased over ICU days 2–7. Inflammation profiling predicted coronavirus disease 2019 status with 98% accuracy, whereas elevated heat shock protein 70 was strongly associated with mortality.
Conclusions:. While many inflammatory analytes were elevated in coronavirus disease 2019 positive ICU patients, relative to healthy controls, the top six analytes distinguishing coronavirus disease 2019 positive ICU patients from coronavirus disease 2019 negative ICU patients were tumor necrosis factor, granzyme B, heat shock protein 70, interleukin-18, interferon-gamma-inducible protein 10, and elastase 2. |
| format |
article |
| author |
Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Marat Slessarev, MD, MSc Claudio Martin, MD, MSc Mark Daley, PhD Michael R. Miller, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Eric K. Patterson, PhD Claudia C. dos Santos, MD, MSc on behalf of the Lawson COVID-19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn |
| author_facet |
Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Marat Slessarev, MD, MSc Claudio Martin, MD, MSc Mark Daley, PhD Michael R. Miller, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Eric K. Patterson, PhD Claudia C. dos Santos, MD, MSc on behalf of the Lawson COVID-19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn |
| author_sort |
Douglas D. Fraser, MD, PhD |
| title |
Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients |
| title_short |
Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients |
| title_full |
Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients |
| title_fullStr |
Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients |
| title_full_unstemmed |
Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients |
| title_sort |
inflammation profiling of critically ill coronavirus disease 2019 patients |
| publisher |
Wolters Kluwer |
| publishDate |
2020 |
| url |
https://doaj.org/article/2e2aee660c2348e2bff3b3144f7398a4 |
| work_keys_str_mv |
AT douglasdfrasermdphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT gediminascepinskasdvmphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT maratslessarevmdmsc inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT claudiomartinmdmsc inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT markdaleyphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT michaelrmillerphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT davidbogormanphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT seanegillphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT erickpattersonphd inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT claudiacdossantosmdmsc inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT onbehalfofthelawsoncovid19studyteam inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT robertarntfield inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT ianball inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT gordonbarkwell inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT traceybentall inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT karenbosma inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT saoirsecameron inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT eileencampbell inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT davidcarter inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT carolinagilliomeina inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT roberthegele inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT natalyaodoardi inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT ramsingh inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT kellysummers inflammationprofilingofcriticallyillcoronavirusdisease2019patients AT suetereschyn inflammationprofilingofcriticallyillcoronavirusdisease2019patients |
| _version_ |
1718413608620130304 |